MDMA, Ketamine · American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2026 · Evidence: Moderate

Open-label trial

Interviews with 10 people given 5-MeO-DMT plus CBT for alcohol use disorder

5-MeO-DMT · Addiction (Abingdon, England), 2026 · Evidence: Very low

Systematic review

Review of esketamine for depression in people with cancer

Esketamine · Frontiers in psychiatry, 2026 · Evidence: Very low

Other

Review: no reliable biological markers yet for bipolar disorder staging or psychedelic effects

Ketamine, Psilocybin, 5-MeO-DMT · Molecular neurobiology, 2026 · Evidence: Very low

Open-label trial

Small open-label pilot of ibogaine for alcohol use disorder: heart rhythm changes seen

Ibogaine · Trends in psychiatry and psychotherapy, 2026 · Evidence: Very low

Systematic review

Review of 11 studies on non-medical psychedelic use and suicidal thoughts

Psilocybin, LSD, DMT, Mescaline · L'Encephale, 2026 · Evidence: Low

Other

What people said about music during psilocybin therapy for life-threatening illness

Psilocybin · Journal of music therapy, 2026 · Evidence: Low

Case report

Single case report: ibogaine treatment followed by 17 months off ketamine, cocaine and alcohol

Ibogaine, Ketamine · Frontiers in psychiatry, 2026 · Evidence: Very low

Meta-analysis

Ketamine and substance use disorders: pooled results from 15 randomized trials

Ketamine · Frontiers in psychiatry, 2026 · Evidence: Moderate

Other

Review of newer treatments for suicidal thoughts finds ayahuasca among promising options

Ayahuasca · European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2026 · Evidence: Low

RCT

Daily oral esketamine did not raise a brain growth protein more than placebo in depression

Esketamine · Journal of affective disorders, 2026 · Evidence: Low

RCT

DMT plus harmine lowered embarrassment during a karaoke task in 28 healthy men

DMT, Other · Psychopharmacology, 2026 · Evidence: Moderate

Systematic review

A scoping review of how psychedelics affect thalamus-to-cortex brain circuits

Ibogaine, Other · Pharmacology, biochemistry, and behavior, 2026 · Evidence: Very low

RCT

Psilocybin lowered two stress-related brain chemicals in spinal fluid in depression trial

Psilocybin · Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2026 · Evidence: Low

RCT

Repeated IV ketamine did not worsen thinking skills in treatment-resistant depression

Ketamine · Pharmacopsychiatry, 2026 · Evidence: Moderate

Systematic review

A review proposing two routes for turning ibogaine into a medicine

Ibogaine · Expert opinion on drug discovery, 2026 · Evidence: Very low

RCT

EEG changes after ketamine in older veterans with treatment-resistant depression

Ketamine · Translational psychiatry, 2026 · Evidence: Low

Meta-analysis

Esketamine nasal spray added to an antidepressant: pooled results from six trials

Esketamine · Frontiers in psychiatry, 2026 · Evidence: Moderate

Meta-analysis

Comparing drug treatments for postpartum depression, including esketamine

Esketamine · Psychiatry research, 2026 · Evidence: Moderate

Systematic review

Most psychedelic trials don't check whether blinding worked — and when they do, it often fails

Psilocybin, LSD, Ketamine, MDMA, Ayahuasca, DMT, Ibogaine · JAMA psychiatry, 2026 · Evidence: Moderate

Meta-analysis

Pooled analysis of 26 trials: IV ketamine rapidly lowers depression and suicidal symptoms

Ketamine · JAMA psychiatry, 2026 · Evidence: Moderate

Observational

Repeated ketamine infusions for arthritis pain: a 38-patient chart review

Ketamine · Pain physician, 2026 · Evidence: Low

Systematic review

Review: can psychedelics and ketamine change how people read social cues?

Ketamine, Psilocybin, MDMA, LSD, Ayahuasca · Psychopharmacology, 2026 · Evidence: Low

Other

A review of psychedelics and ketamine for depression that has not responded to treatment

Psilocybin, Ketamine, Esketamine, Ayahuasca · Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater, 2026 · Evidence: Low

Systematic review

Review of microdosing research finds no cognitive boost, and a small dip in cognitive control

LSD, Psilocybin · Journal of psychopharmacology (Oxford, England), 2026 · Evidence: Moderate

Systematic review

Review maps the talk-therapy and support protocols used in psychedelic trials

Psilocybin, MDMA, LSD, DMT, 5-MeO-DMT, Ayahuasca, Ibogaine, Mescaline, Other · Journal of psychopharmacology (Oxford, England), 2026 · Evidence: Low

RCT

Morning cortisol rose 24 hours after ketamine in a trial for suicidal depression

Ketamine · Journal of affective disorders, 2026 · Evidence: Low

Other

Narrative review of psychedelics, psychosis risk and schizophrenia spectrum disorders

Other · Journal of psychopharmacology (Oxford, England), 2026 · Evidence: Very low

Meta-analysis

What predicts improvement when ketamine is paired with therapy for PTSD

Ketamine · Psychotherapy and psychosomatics, 2026 · Evidence: Low

RCT

LSD in healthy volunteers: effects on motor learning, stress and brain signals up to a week

LSD · Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2026 · Evidence: Moderate

Other

Review of what is known about mescaline's safety and therapeutic potential in humans

Mescaline · American journal of therapeutics, 2026 · Evidence: Low

Observational

Esketamine nasal spray in hard-to-treat depression, with and without borderline personality disorder

Esketamine · Psychiatry research, 2026 · Evidence: Low

RCT

How depression symptoms change over 32 weeks with esketamine nasal spray

Esketamine · European psychiatry : the journal of the Association of European Psychiatrists, 2026 · Evidence: Low

RCT

Ketamine boosted deep-sleep brain waves in treatment-resistant depression, not in healthy people

Ketamine · Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2026 · Evidence: Moderate

Observational

Brain responses to predictable images differ in people who recently used psychedelics

Psilocybin, LSD, 5-MeO-DMT · bioRxiv : the preprint server for biology, 2026 · Evidence: Very low

Systematic review

How music is chosen and used in psychedelic-assisted therapy trials: a systematic review

Psilocybin, MDMA · Journal of clinical psychology, 2026 · Evidence: Low

Systematic review

Review of human studies on dextromethorphan's psychedelic-like effects and doses

Other · CNS drugs, 2026 · Evidence: Low

Systematic review

Review finds only six human studies on psychedelics and ADHD, and weak evidence overall

LSD, Psilocybin, DMT, MDMA, Mescaline, Ketamine, Other · Acta neuropsychiatrica, 2026 · Evidence: Low

RCT

Inhaled 5-MeO-DMT (GH001) worked regardless of how many antidepressants had failed before

5-MeO-DMT · Psychopharmacology bulletin, 2026 · Evidence: Low

RCT

Does a second, smaller MDMA dose extend the drug's effects? A crossover trial in 25 adults

MDMA · Translational psychiatry, 2026 · Evidence: Moderate

Open-label trial

Psilocybin and anxiety, quality of life and functioning in 15 veterans with hard-to-treat depression

Psilocybin · Journal of affective disorders, 2026 · Evidence: Very low

Other

Review of classic psychedelics for chronic pain: early signals, weak evidence so far

Psilocybin, LSD, DMT, Ayahuasca, Mescaline · Drugs, 2026 · Evidence: Low

Open-label trial

Inhaled 5-MeO-DMT in 10 women with postpartum depression: an open-label phase 2a trial

5-MeO-DMT · The Journal of clinical psychiatry, 2026 · Evidence: Very low

RCT

Pilot trial tests whether a ketamine study is feasible for teens in the emergency department

Ketamine · CJEM, 2026 · Evidence: Very low

Case series

Three people with brain injury symptoms improved during low-dose iboga plus therapy

Ibogaine · Frontiers in pharmacology, 2026 · Evidence: Very low

RCT

Inhaled 5-MeO-DMT (GH001) vs placebo for treatment-resistant depression: phase 2b trial

5-MeO-DMT · JAMA psychiatry, 2026 · Evidence: Moderate

RCT

Oral DMT plus harmine raised whole-brain glucose use by 12.5% in 14 healthy men

DMT, Ayahuasca · Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2026 · Evidence: Very low

Systematic review

Review of 30 years of ibogaine research finds evidence too weak to support clinical use

Ibogaine · Journal of clinical psychopharmacology, 2026 · Evidence: Low

RCT

Slow-release ketamine tablets caused little dissociation but missed their depression target

Ketamine, Esketamine · JAMA network open, 2026 · Evidence: Moderate

Observational

What people with hard-to-treat depression hope for when joining psychedelic trials

Psilocybin, 5-MeO-DMT · Brain and behavior, 2026 · Evidence: Very low

Systematic review

Review of 48 studies: psychedelics linked to more Openness and less Neuroticism

Psilocybin, LSD, DMT, Ayahuasca, Mescaline · Journal of psychopharmacology (Oxford, England), 2026 · Evidence: Low

Systematic review

Review of 18 trials finds oral ketamine mostly causes mild, short-lived side effects

Ketamine, Esketamine · Psychiatry and clinical neurosciences, 2026 · Evidence: Low

Meta-analysis

How often do psychedelics trigger mania or hypomania? A review of 23 studies

Psilocybin, LSD, MDMA, DMT, Ayahuasca, Mescaline · Molecular psychiatry, 2026 · Evidence: Low

Systematic review

Review of how the body handles LSD, psilocybin, DMT, mescaline and 5-MeO-DMT

LSD, Psilocybin, DMT, 5-MeO-DMT, Mescaline · Journal of psychopharmacology (Oxford, England), 2026 · Evidence: Low

Systematic review

Review of ketamine for depression in adults with cancer: fast relief, limited long-term data

Ketamine · Journal of pain & palliative care pharmacotherapy, 2026 · Evidence: Low

RCT

Can people tell which drug they got? Blinding tested in a psilocybin and MDMA trial

Psilocybin, MDMA, Other · European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2026 · Evidence: Moderate

Meta-analysis

Esketamine side effects in treatment-resistant depression rise with higher doses

Esketamine · Frontiers in pharmacology, 2026 · Evidence: Moderate

RCT

Psilocybin and DNA methylation changes in 37 people treated for alcohol use disorder

Psilocybin · Translational psychiatry, 2026 · Evidence: Low

Observational

Voice diaries before and after a 5-MeO-DMT retreat showed shifts in language and voice

5-MeO-DMT · Journal of psychopharmacology (Oxford, England), 2026 · Evidence: Low

Case series

Interviews with 10 people who used ibogaine for opioid detox in New Zealand

Ibogaine · Journal of psychoactive drugs, 2026 · Evidence: Very low

Observational

Sleep and appetite changes were the most reported new symptoms during ketamine infusions for depression

Ketamine · Pharmacological reports : PR, 2026 · Evidence: Low

Observational

UK nightclub deaths 2009-2024: trauma and MDMA toxicity were the leading causes

MDMA · Emergency medicine journal : EMJ, 2026 · Evidence: Low

RCT

Low-dose buprenorphine after a ketamine infusion and suicidal thoughts in depression

Ketamine, Other · The American journal of psychiatry, 2026 · Evidence: Moderate

Meta-analysis

Oral ketamine for depression: review of 8 randomized trials with 414 people

Ketamine · Asian journal of psychiatry, 2026 · Evidence: Moderate

Systematic review

Review finds few reliable predictors of who responds to ketamine for depression

Ketamine, Esketamine · CNS drugs, 2026 · Evidence: Low

Open-label trial

Single dose of psilocybin in 20 adults with chronic suicidal thoughts: open-label trial

Psilocybin · The Journal of clinical psychiatry, 2026 · Evidence: Low

Systematic review

Review of human ibogaine research finds only three randomized trials and real cardiac risks

Ibogaine, 5-MeO-DMT · Journal of psychopharmacology (Oxford, England), 2026 · Evidence: Low

Systematic review

A review of 26 registered clinical trials of ayahuasca and DMT

DMT, Ayahuasca · Clinical pharmacology and therapeutics, 2026 · Evidence: Low

Systematic review

Review: IV ketamine for treatment-resistant depression showed no cognitive decline

Ketamine · Psychological medicine, 2026 · Evidence: Low

RCT

Brain scans after LSD treatment for depression show white matter changes

LSD · Cell reports. Medicine, 2026 · Evidence: Low

Systematic review

Review of how ketamine affects sleep and body-clock rhythms in depression and bipolar disorder

Ketamine, Esketamine · Journal of affective disorders, 2026 · Evidence: Low

RCT

Adding CBT to esketamine for depression with suicidal thoughts: a randomized trial

Esketamine · The Journal of clinical psychiatry, 2026 · Evidence: Moderate

RCT

Blocking a serotonin receptor with pindolol made DMT's effects feel stronger

DMT · Journal of psychopharmacology (Oxford, England), 2026 · Evidence: Very low

Other

Psilocybin and other psychedelics showed no reliable effect on authoritarian attitudes

Psilocybin, Other · Journal of psychopharmacology (Oxford, England), 2026 · Evidence: Low

Observational

Blood inflammation marker linked to esketamine response in 16 people with hard-to-treat depression

Esketamine · Journal of clinical psychopharmacology, 2026 · Evidence: Very low

Observational

Meditators scored higher than ayahuasca users on a measure of loosened self-focus

Ayahuasca · Human psychopharmacology, 2026 · Evidence: Low

RCT

Psilocybin for treatment-resistant depression: no significant benefit at 6 weeks

Psilocybin · JAMA psychiatry, 2026 · Evidence: Moderate

Meta-analysis

Psychedelic therapy no better than open-label antidepressants for depression, review finds

Other · JAMA psychiatry, 2026 · Evidence: Moderate

RCT

Single psilocybin dose eased depression for months, but not at one year

Psilocybin · JAMA network open, 2026 · Evidence: Moderate

RCT

Single psilocybin dose with therapy increased cocaine abstinence in a 40-person trial

Psilocybin · JAMA network open, 2026 · Evidence: Moderate

RCT

2C-B compared head-to-head with MDMA and psilocybin in 24 healthy volunteers

2C-B, MDMA, Psilocybin · Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2026 · Evidence: Moderate

RCT

Intranasal ketamine and existential distress in advanced cancer: secondary trial results

Ketamine · Journal of pain and symptom management, 2026 · Evidence: Very low

Other

Brain iron-related MRI signals and response to repeated ketamine in treatment-resistant depression

Ketamine · Psychiatry research. Neuroimaging, 2026 · Evidence: Very low

RCT

A common gene variant linked to higher blood levels of oral esketamine

Esketamine · The pharmacogenomics journal, 2026 · Evidence: Very low

Open-label trial

Could a blood inflammation marker predict who responds to esketamine for depression?

Esketamine · Journal of psychopharmacology (Oxford, England), 2026 · Evidence: Very low

Observational

Blood chemistry, brain networks and the ayahuasca experience in 20 ceremonial users

Ayahuasca, DMT · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2026 · Evidence: Very low

Systematic review

Systematic review: ayahuasca and suicidal thoughts in hard-to-treat depression

Ayahuasca, DMT · Journal of psychoactive drugs, 2026 · Evidence: Low

Observational

IV ketamine in real-world care: bigger, faster gains in bipolar than unipolar depression

Ketamine · Psychiatry research, 2026 · Evidence: Low

Observational

Esketamine and suicidal thoughts in treatment-resistant depression, with and without borderline PD

Esketamine · Asian journal of psychiatry, 2026 · Evidence: Low

Systematic review

Review of liver safety in ketamine treatment for mood and anxiety disorders

Ketamine · General hospital psychiatry, 2026 · Evidence: Low

Systematic review

How long do people stay well after ECT versus ketamine? A review of 13 studies

Ketamine, Esketamine · Journal of psychopharmacology (Oxford, England), 2026 · Evidence: Low

Open-label trial

A second group psilocybin session for cancer patients who only partly improved the first time

Psilocybin · Frontiers in public health, 2026 · Evidence: Very low

Systematic review

Review of psychedelics for adult ADHD finds no proof of benefit

LSD, Ayahuasca, Other · International journal of molecular sciences, 2026 · Evidence: Low

Meta-analysis

Review pools DMT studies for substance misuse and finds large but unreliable effects

DMT, 5-MeO-DMT · Journal of psychopharmacology (Oxford, England), 2026 · Evidence: Low

Other

Training nurses to support psilocybin sessions: modest gains in relational skills

Psilocybin · BMC medical education, 2026 · Evidence: Very low

Observational

Who does not improve on anhedonia after ketamine? A small study of 34 inpatients

Ketamine · Journal of affective disorders, 2026 · Evidence: Low

Other

Review of where psychedelic-assisted therapies stand in the clinic and in regulation

Ketamine, Esketamine, Psilocybin, MDMA, LSD, DMT, 5-MeO-DMT, Ibogaine · Expert opinion on pharmacotherapy, 2026 · Evidence: Very low

RCT

Pilot trial of a single ketamine infusion for teens with suicidal thoughts in the ER

Ketamine · BMC psychiatry, 2026 · Evidence: Very low

Meta-analysis

Pooled brain scan data from 11 psychedelic studies finds a shared connectivity pattern

Psilocybin, LSD, Mescaline, DMT, Ayahuasca · Nature medicine, 2026 · Evidence: Low

RCT

Blocking opioid receptors did not change ketamine's effects on brain blood flow in depression

Ketamine · The American journal of psychiatry, 2026 · Evidence: Moderate

Systematic review

Review finds very little human safety data on psychedelic use during pregnancy

MDMA, LSD, Psilocybin, DMT, Ayahuasca, Mescaline · Therapeutic advances in drug safety, 2026 · Evidence: Very low

Systematic review

How cognitive behavioural therapy is combined with psychedelics: a review of 9 trials

Ketamine, Psilocybin, MDMA · European archives of psychiatry and clinical neuroscience, 2026 · Evidence: Low

Systematic review

Review of mescaline studies finds too little good evidence for psychiatric use

Mescaline · International journal of molecular sciences, 2026 · Evidence: Very low

RCT

How intravenous DMT doses affect the body and mind in healthy volunteers

DMT · Translational psychiatry, 2026 · Evidence: Moderate

Systematic review

Review of interview studies: how psychedelics change how seriously ill people view death

Other · Journal of pain and symptom management, 2026 · Evidence: Low

Systematic review

Review: esketamine did not worsen thinking skills in treatment-resistant depression

Esketamine · Journal of clinical psychopharmacology, 2026 · Evidence: Low

RCT

Does the therapist relationship drive psilocybin's effect on hard-to-treat depression?

Psilocybin · Journal of affective disorders, 2026 · Evidence: Low

Meta-analysis

Meta-analysis of six trials: standard-dose psilocybin reduced depression symptoms

Psilocybin · Journal of affective disorders, 2026 · Evidence: Moderate

Observational

Esketamine nasal spray in routine care: 50 patients with treatment-resistant depression tracked

Esketamine · Journal of psychopharmacology (Oxford, England), 2026 · Evidence: Low

Systematic review

Does the "therapy" in psychedelic-assisted therapy trials count as real psychotherapy?

Psilocybin, MDMA, LSD · Journal of psychopharmacology (Oxford, England), 2026 · Evidence: Low

Survey

Survey of 203 ayahuasca ceremony attenders in Portugal reports better self-rated health

Ayahuasca · Journal of psychoactive drugs, 2026 · Evidence: Low

RCT

What experienced meditators said about meditating on DMT-harmine versus placebo

DMT, Other · Scientific reports, 2026 · Evidence: Low

Observational

Ayahuasca retreat for LGBTQ+ participants linked to lower depression and anxiety scores

Ayahuasca · Journal of psychoactive drugs, 2026 · Evidence: Low

RCT

Repeated psilocybin doses for OCD: a small randomized phase 1 trial in 15 people

Psilocybin · Journal of psychopharmacology (Oxford, England), 2026 · Evidence: Very low

Meta-analysis

MDMA-assisted therapy for PTSD: pooled trial results show symptom drops but very low certainty

MDMA · European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2026 · Evidence: Low

Observational

Esketamine nasal spray in real-world care: depression scores fell over 4 weeks

Esketamine · Journal of psychiatric research, 2026 · Evidence: Low

Systematic review

What brain scans show about ketamine and reward circuits in depression: a systematic review

Ketamine · CNS spectrums, 2026 · Evidence: Low

Other

A review of the case for and against psychedelic therapy for postpartum depression

Other · Therapeutic advances in psychopharmacology, 2026 · Evidence: Very low

Systematic review

Review of 16 studies on how ayahuasca affects thinking skills and social cognition

Ayahuasca · Journal of psychopharmacology (Oxford, England), 2026 · Evidence: Low

Meta-analysis

Review pooling 8 studies finds psychedelic experiences linked to lower death anxiety

Other · Journal of psychopharmacology (Oxford, England), 2026 · Evidence: Low

RCT

Why oral (S)-ketamine feels different: a metabolite may drive the subjective effects

Esketamine · British journal of clinical pharmacology, 2026 · Evidence: Very low

RCT

Psilocybin vs nicotine patch for quitting smoking: a pilot randomized trial

Psilocybin · JAMA network open, 2026 · Evidence: Moderate

Systematic review

Brain scan markers that may predict who responds to ketamine for depression

Ketamine · Journal of affective disorders, 2026 · Evidence: Low

Open-label trial

Esketamine nasal spray over two extra years: relapse and side effects in hard-to-treat depression

Esketamine · European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2026 · Evidence: Low

Open-label trial

Single dose of intranasal 5-MeO-DMT in 12 people with treatment-resistant depression

5-MeO-DMT · Journal of psychopharmacology (Oxford, England), 2026 · Evidence: Very low

Other

Which patients respond best to ketamine for suicidal thoughts? A post-hoc analysis of 67 people

Ketamine · Pharmacopsychiatry, 2026 · Evidence: Low

Other

Review of ayahuasca, DMT and 5-MeO-DMT as possible treatments for mental disorders

DMT, 5-MeO-DMT, Ayahuasca · Biomedicines, 2026 · Evidence: Low

Systematic review

Review finds little evidence that lesser-known tryptamine psychedelics help alcohol use disorder

Other · Psychedelic medicine (New Rochelle, N.Y.), 2026 · Evidence: Low

Open-label trial

Single ketamine infusion in 13 older adults with depression and mild memory loss

Ketamine · The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2026 · Evidence: Very low

RCT

Esketamine infusions did not change inflammation markers in depressed teens

Esketamine · Journal of affective disorders, 2026 · Evidence: Low

Observational

Brain scans after magnesium-ibogaine treatment in 30 veterans with blast brain injury

Ibogaine · iScience, 2026 · Evidence: Low

Other

Review: how salvinorin A acts on opioid receptors rather than serotonin receptors

Salvinorin A, Psilocybin, LSD, Other · Biomedicines, 2026 · Evidence: Very low

Observational

National survey links psychedelic use to opioid use disorder severity — in both directions

Mescaline, LSD, Psilocybin, MDMA, DMT · Addictive behaviors, 2026 · Evidence: Low

Other

Computer models predict higher ayahuasca alkaloid levels when combined with SSRIs

Ayahuasca, DMT · Frontiers in molecular biosciences, 2026 · Evidence: Very low

Meta-analysis

Placebo groups in psychedelic trials also improved, but less than treatment groups

Other · European psychiatry : the journal of the Association of European Psychiatrists, 2026 · Evidence: Moderate

Open-label trial

LSD microdosing for depression: mood, drug levels and tolerance in a small open-label trial

LSD · Progress in neuro-psychopharmacology & biological psychiatry, 2026 · Evidence: Very low

RCT

A single IV dose of DMT lowered depression scores more than placebo in a 34-person trial

DMT · Nature medicine, 2026 · Evidence: Moderate

Open-label trial

Psilocybin paired with cognitive behavioural therapy for depression: a 16-person pilot trial

Psilocybin · Journal of affective disorders, 2026 · Evidence: Very low

Systematic review

Review of 32 placebo-controlled studies on how LSD, DMT and psilocybin affect thinking

LSD, DMT, Psilocybin · Journal of psychopharmacology (Oxford, England), 2026 · Evidence: Moderate

Other

Review of how ibogaine might repair nerve insulation and brain energy use

Ibogaine · Acta neuropsychiatrica, 2026 · Evidence: Very low

Observational

Long-term ayahuasca and cannabis users differed in personality, not thinking skills

Ayahuasca, Other · European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2026 · Evidence: Low

RCT

Psilocybin with psychotherapy and loss of pleasure in treatment-resistant depression

Psilocybin · Journal of affective disorders, 2026 · Evidence: Low

Meta-analysis

Review of 7 psilocybin trials in major depression looks at dose and number of sessions

Psilocybin · European archives of psychiatry and clinical neuroscience, 2026 · Evidence: Moderate

Systematic review

Review of how ketamine and related drugs affect sleep in depression

Ketamine, Esketamine, Other · Journal of psychiatric research, 2026 · Evidence: Low

Open-label trial

Brain imaging before and after ibogaine treatment in 30 veterans with brain injury

Ibogaine · Biological psychiatry. Cognitive neuroscience and neuroimaging, 2026 · Evidence: Low

Systematic review

Review of 18 long-term studies on ayahuasca and mental and physical health

Ayahuasca · Progress in neuro-psychopharmacology & biological psychiatry, 2026 · Evidence: Low

Systematic review

Review finds no reliable way to predict who responds to ketamine, ECT or TMS for depression

Ketamine, Esketamine · International journal of psychiatry in clinical practice, 2026 · Evidence: Low

Systematic review

Review of ketamine combined with psychotherapy for hard-to-treat depression

Ketamine · Psychopharmacology, 2026 · Evidence: Low

Other

Expert group outlines four recurring problems in psychedelic clinical trials

Psilocybin, LSD, DMT, Mescaline · Journal of psychopharmacology (Oxford, England), 2026 · Evidence: Very low

RCT

Ketamine vs. electroconvulsive therapy for severe depression with suicidal thoughts

Ketamine · Neuropsychobiology, 2026 · Evidence: Moderate

Systematic review

Review of heart valve risks from repeated LSD and MDMA use

LSD, MDMA, Psilocybin · Pharmacopsychiatry, 2026 · Evidence: Low

Systematic review

Scoping review of ibogaine for addiction: promise, patchy evidence and heart safety concerns

Ibogaine · Molecules (Basel, Switzerland), 2026 · Evidence: Low

RCT

Brain imaging comparison of 2C-B and psilocybin in 22 healthy volunteers

Psilocybin, 2C-B · Molecular psychiatry, 2026 · Evidence: Moderate

Systematic review

Review of ketamine combined with psychotherapy: little proof the therapy part adds benefit

Ketamine · Clinical psychology review, 2026 · Evidence: Low

Other

How people in a psilocybin therapy trial experienced supportive touch

Psilocybin · Brain and behavior, 2026 · Evidence: Very low

Meta-analysis

Ketamine vs midazolam for suicidal thoughts: pooled results from 10 randomized trials

Ketamine · Brain and behavior, 2026 · Evidence: Moderate

Open-label trial

What veterans described after a single ibogaine session for PTSD and brain injury

Ibogaine · Npj mental health research, 2026 · Evidence: Low

Open-label trial

Small open-label trial of low-dose psilocybin for distress in palliative care patients

Psilocybin · Palliative medicine, 2026 · Evidence: Very low

Observational

Depression scores after ritual ayahuasca use tracked for six months in 280 patients

Ayahuasca · Frontiers in psychiatry, 2026 · Evidence: Low

Systematic review

Does ketamine's antidepressant effect work partly through the opioid system?

Ketamine, Esketamine · European psychiatry : the journal of the Association of European Psychiatrists, 2026 · Evidence: Low

Meta-analysis

Pooled real-world data on nasal esketamine for hard-to-treat depression

Esketamine · Journal of affective disorders, 2026 · Evidence: Low

RCT

Psilocybin shifted brain-wave patterns in 25 healthy volunteers in a crossover trial

Psilocybin · Progress in neuro-psychopharmacology & biological psychiatry, 2026 · Evidence: Moderate

RCT

Psilocybin did not shift personality or symptoms, but did shift reported personal values

Psilocybin · Journal of psychopharmacology (Oxford, England), 2026 · Evidence: Low

Meta-analysis

Review of 7 trials finds psilocybin therapy reduces depression scores; setup details less clear

Psilocybin · Neuroscience and biobehavioral reviews, 2026 · Evidence: Moderate

Meta-analysis

ECT vs ketamine for depression: meta-analysis finds ECT improves symptoms faster

Ketamine · Translational psychiatry, 2026 · Evidence: Moderate

Systematic review

Comparing lithium, quetiapine and esketamine as add-ons for hard-to-treat depression

Esketamine, Ketamine · The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2026 · Evidence: Low

RCT

Ayahuasca changed brain connectivity in social-perception regions in 12 healthy adults

Ayahuasca, DMT · Social cognitive and affective neuroscience, 2026 · Evidence: Very low

Observational

Nasal ketamine vs esketamine for hard-to-treat depression: similar scores, fewer remissions

Ketamine, Esketamine · Journal of affective disorders, 2026 · Evidence: Low

Other

Review of ibogaine's heart risks: QT prolongation and dangerous arrhythmias

Ibogaine · Addiction (Abingdon, England), 2026 · Evidence: Low

Observational

Two common transporter gene variants did not change oral esketamine blood levels (n=18)

Esketamine · Pharmacogenomics, 2026 · Evidence: Very low

RCT

What people said the day after psilocybin linked to staying off alcohol at 3 months

Psilocybin · Journal of affective disorders, 2026 · Evidence: Low

Other

Review of MAOI antidepressants mixed with psychedelics and other psychoactive drugs

MDMA, DMT, 5-MeO-DMT, Psilocybin, 2C-B, Other · CNS drugs, 2026 · Evidence: Very low

RCT

Low-dose LSD and brain responses to reward in people with mild depressed mood

LSD · Journal of psychopharmacology (Oxford, England), 2026 · Evidence: Moderate

Meta-analysis

Review of 21 studies: ketamine linked to large short-term drops in suicidal thinking

Ketamine · Epidemiology and psychiatric sciences, 2026 · Evidence: Moderate

Systematic review

Systematic review of psychedelic trials for treatment-resistant depression

Other · Journal of clinical psychopharmacology, 2026 · Evidence: Moderate

Observational

Esketamine's effect on suicidal thoughts appears tied to its effect on depression

Esketamine · Journal of affective disorders, 2026 · Evidence: Low

Systematic review

Review of drugs that alter fear memory in healthy people, including MDMA

MDMA · Neuroscience and biobehavioral reviews, 2026 · Evidence: Low

Observational

US poison centre reports on psychoactive mushroom edibles, 2023-2024

Psilocybin, Other · Clinical toxicology (Philadelphia, Pa.), 2026 · Evidence: Low

Meta-analysis

Pooled review: psilocybin and psychological distress in people with cancer

Psilocybin · BMC psychology, 2026 · Evidence: Moderate

Survey

What safety steps do advertised psychedelic retreats actually use? A study of 49 organizations

Psilocybin, Ayahuasca · JAMA network open, 2026 · Evidence: Low

Other

A clinician's review of 5-MeO-DMT research for depression

5-MeO-DMT · American journal of therapeutics, 2026 · Evidence: Low

Other

A review of psychedelics and ketamine as fast-acting treatments for depression

Psilocybin, Ayahuasca, Ketamine, Esketamine · Advances in experimental medicine and biology, 2026 · Evidence: Very low

Other

A review of psychosis linked to classic psychedelics and how it compares to primary psychosis

LSD, Psilocybin, Mescaline · Current topics in behavioral neurosciences, 2026 · Evidence: Very low

Other

A review proposing how to classify harms linked to psychedelic use

Psilocybin, LSD, 5-MeO-DMT · Current topics in behavioral neurosciences, 2026 · Evidence: Very low

RCT

Psilocybin made time feel slower and less precise in 24 healthy volunteers

Psilocybin · Journal of psychopharmacology (Oxford, England), 2026 · Evidence: Moderate

Systematic review

Review of drugs for anxiety at the end of life, including psilocybin

Psilocybin · Human psychopharmacology, 2026 · Evidence: Low

Other

Stress hormone marker was lower in people with both depression and PTSD, before and after ketamine

Ketamine · Journal of neuroendocrinology, 2026 · Evidence: Low

Systematic review

Review asks how long ketamine's brain-plasticity window lasts and what that means for dosing

Ketamine, Esketamine · Journal of affective disorders, 2025 · Evidence: Low

RCT

Psilocybin versus active placebo for migraine prevention: small trial finds no clear difference

Psilocybin, Other · Headache, 2025 · Evidence: Very low

Systematic review

Review of 23 meta-analyses on psychedelic-assisted therapy for mental disorders

Psilocybin, MDMA, LSD, Ayahuasca · Journal of clinical medicine, 2025 · Evidence: Moderate

Observational

What adverse events are reported for psychedelics and MDMA in a global safety database

MDMA, LSD, Psilocybin, DMT, Mescaline · Psychiatry research, 2025 · Evidence: Low

Other

A shorter, updated questionnaire for measuring psychedelic experiences: the 3D-ASCr

Psilocybin, LSD, DMT, Mescaline · Journal of psychopharmacology (Oxford, England), 2025 · Evidence: Low

Systematic review

Review of psilocybin therapy for depression and anxiety in palliative care patients

Psilocybin · Palliative medicine, 2025 · Evidence: Low

Other

A review of ibogaine as a possible treatment for opioid dependence

Ibogaine · Substance use & misuse, 2025 · Evidence: Very low

RCT

Ketamine drip for acute injury pain linked to lower PTSD and anxiety scores at 6 months

Ketamine · The journal of trauma and acute care surgery, 2025 · Evidence: Moderate

Meta-analysis

Review pools psilocybin trials and reports large drops in depression and anxiety scores

Psilocybin · Journal of affective disorders, 2025 · Evidence: Low

Open-label trial

Pilot study of a single nasal ketamine dose for acute suicidal thoughts in 12 patients

Ketamine · Psychiatry research, 2025 · Evidence: Very low

Systematic review

Systematic review of how classic psychedelics act in the brain, from receptors to networks

Psilocybin, LSD, DMT · Neuroscience and biobehavioral reviews, 2025 · Evidence: Low

Observational

Cognitive scores after 5-day ketamine infusions for hard-to-treat chronic migraine

Ketamine · CNS drugs, 2025 · Evidence: Low

Systematic review

What predicts who responds to psychedelic-assisted therapy? A review of 54 studies

Psilocybin, LSD, Other · Journal of psychopharmacology (Oxford, England), 2025 · Evidence: Low

Other

Interviews with terminally ill people before and after psilocybin-assisted therapy

Psilocybin · General hospital psychiatry, 2025 · Evidence: Very low

Open-label trial

Single dose of inhaled 5-MeO-DMT plus therapy in 13 people with alcohol use disorder

5-MeO-DMT · Addiction (Abingdon, England), 2025 · Evidence: Very low

Systematic review

Only 3 of 27 US psychedelic therapy trials used community-engaged research methods

Psilocybin, MDMA, LSD · Neuroscience and biobehavioral reviews, 2025 · Evidence: Low

RCT

Ayahuasca changed brain waves and experiences in 50 healthy volunteers

Ayahuasca · Journal of psychopharmacology (Oxford, England), 2025 · Evidence: Moderate

Systematic review

Review of 78 studies on ketamine and esketamine for anxiety in anxiety disorders and depression

Ketamine, Esketamine · Journal of psychopharmacology (Oxford, England), 2025 · Evidence: Low

RCT

Repeated ketamine infusions no better than midazolam for depressed inpatients

Ketamine · JAMA psychiatry, 2025 · Evidence: Moderate

Systematic review

Review of newer treatments for hard-to-treat depression, including ketamine and psychedelics

Ketamine, Esketamine, Other · Actas espanolas de psiquiatria, 2025 · Evidence: Low

Systematic review

Review of seven trials of IV ketamine for PTSD finds mixed but promising results

Ketamine · Acta psychiatrica Scandinavica, 2025 · Evidence: Moderate

Meta-analysis

MDMA and social cognition: pooled results on empathy and reading facial emotions

MDMA · Scientific reports, 2025 · Evidence: Low

Meta-analysis

Re-analysis of esketamine trials finds a small benefit for treatment-resistant depression

Esketamine · BMC medicine, 2025 · Evidence: Moderate

RCT

Ketamine, antidepressants and online CBT did not change goal-directed planning in depression

Ketamine · Translational psychiatry, 2025 · Evidence: Moderate

Meta-analysis

Microdosing review: no cognitive boost, and a small drop in cognitive control

Psilocybin, LSD · Neuroscience and biobehavioral reviews, 2025 · Evidence: Moderate

Survey

Survey of 581 experienced psychedelic users on advice for a first psychedelic experience

Psilocybin, MDMA, DMT, 5-MeO-DMT, Ayahuasca, Salvinorin A, Other · Harm reduction journal, 2025 · Evidence: Low

RCT

Thyroid hormone levels linked to ketamine response in bipolar depression, not major depression

Ketamine · Journal of affective disorders, 2025 · Evidence: Low

Other

Thinking skills after psilocybin therapy for treatment-resistant depression: small gains

Psilocybin · Progress in neuro-psychopharmacology & biological psychiatry, 2025 · Evidence: Low

Observational

Esketamine nasal spray and quality of life in 18 people with treatment-resistant depression

Esketamine · Journal of clinical psychopharmacology, 2025 · Evidence: Very low

Open-label trial

Capsules combining DMT and harmala alkaloids produced strong altered states in 9 volunteers

DMT, Ayahuasca · Scientific reports, 2025 · Evidence: Very low

Meta-analysis

Do two psychedelic dosing sessions beat one? A review of 23 depression and anxiety trials

Other · Journal of affective disorders, 2025 · Evidence: Moderate

Meta-analysis

Memory differences in past ecstasy users persisted after at least 6 months without MDMA

MDMA · Journal of psychopharmacology (Oxford, England), 2025 · Evidence: Low

Observational

Stronger "mystical" experiences during ibogaine linked to bigger PTSD drops in 30 veterans

Ibogaine · Journal of affective disorders, 2025 · Evidence: Low

Systematic review

Review of brain markers linked to reduced suicidal thoughts, including with IV ketamine

Ketamine · Translational psychiatry, 2025 · Evidence: Low

RCT

Psilocybin and escitalopram both reduced negative bias in reading faces in depression

Psilocybin · Translational psychiatry, 2025 · Evidence: Low

Observational

Long-term ayahuasca users report less fear of death, but brain markers of denial persist

Ayahuasca · Psychopharmacology, 2025 · Evidence: Low

Observational

Nine people describe combining psychedelics with 12-Step recovery from addiction

Ayahuasca, Ibogaine, Psilocybin, Mescaline · Journal of psychoactive drugs, 2025 · Evidence: Very low

Meta-analysis

Ketamine for teen depression: pooled trials show no clear mood benefit at 24 hours

Ketamine · International review of psychiatry (Abingdon, England), 2025 · Evidence: Moderate

Meta-analysis

Pooled review of 30 trials of MDMA and psychedelics for mental disorders

MDMA, Psilocybin, LSD, Ayahuasca · European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2025 · Evidence: Moderate

RCT

What intranasal 5-MeO-DMT feels like: interviews with 32 psychedelic-naive adults

5-MeO-DMT · Scientific reports, 2025 · Evidence: Low

Open-label trial

Eight weeks of low-dose LSD in 19 people with depression: an open-label safety trial

LSD · Neuropharmacology, 2025 · Evidence: Very low

RCT

Ketamine and psilocybin change brain wave patterns in different ways, EEG re-analysis finds

Esketamine, Psilocybin · Psychopharmacology, 2025 · Evidence: Low

RCT

Psilocybin microdosing and creativity: pooled results from three placebo-controlled trials

Psilocybin · Neuropharmacology, 2025 · Evidence: Moderate

RCT

Comparing 3-, 5- and 7-day ketamine infusion schedules for complex regional pain syndrome

Ketamine · Pain physician, 2025 · Evidence: Moderate

Open-label trial

Ketamine infusions and markers of biological aging in 20 people with depression or PTSD

Ketamine · Translational psychiatry, 2025 · Evidence: Very low

Systematic review

Review of brain imaging studies on psychedelics and ketamine for depression

Ketamine, Esketamine, Psilocybin, LSD, DMT, Ayahuasca · Translational psychiatry, 2025 · Evidence: Low

Systematic review

Review: esketamine improved day-to-day and work functioning in depression; no ketamine trials found

Esketamine, Ketamine · Journal of psychiatric research, 2025 · Evidence: Moderate

Meta-analysis

Side effects of ketamine and esketamine for depression: a review of 47 studies

Ketamine, Esketamine · Frontiers in pharmacology, 2025 · Evidence: Moderate

Meta-analysis

Esketamine for depression: pooled results from 67 randomized trials

Esketamine · Molecular psychiatry, 2025 · Evidence: Moderate

Other

Review of ayahuasca research finds little controlled evidence for mental health uses

Ayahuasca · Expert review of clinical pharmacology, 2025 · Evidence: Very low

Systematic review

Ketamine and esketamine for hard-to-treat depression in youth: a review of the evidence

Ketamine, Esketamine · European child & adolescent psychiatry, 2025 · Evidence: Low

Systematic review

Review of side effects reported in 42 psilocybin trials involving 1,068 people

Psilocybin · Progress in neuro-psychopharmacology & biological psychiatry, 2025 · Evidence: Moderate

Meta-analysis

Review pools 30 studies of psychedelics and ketamine for substance use disorder

LSD, Psilocybin, Ketamine, Ibogaine · Healthcare (Basel, Switzerland), 2025 · Evidence: Low

Survey

Survey of 5-MeO-DMT users: 69% reported later "reactivations", mostly positive or neutral

5-MeO-DMT · Journal of psychoactive drugs, 2025 · Evidence: Low

Systematic review

A review of 241 registered psychedelic clinical trials and how the field has changed

Psilocybin, LSD, DMT, 5-MeO-DMT · Journal of psychopharmacology (Oxford, England), 2025 · Evidence: Low

Meta-analysis

Ketamine vs electroconvulsive therapy for hard-to-treat depression: pooled results

Ketamine · International journal of psychiatry in clinical practice, 2025 · Evidence: Moderate

Other

Review: how psychedelics and ketamine may reshape brain connections in depression, PTSD and addiction

Ketamine, MDMA, Ibogaine, Other · Progress in neuro-psychopharmacology & biological psychiatry, 2025 · Evidence: Very low

Observational

People with bipolar disorder who used psychedelics vs. those only considering it

Psilocybin, LSD · Journal of affective disorders, 2025 · Evidence: Low

RCT

Psilocybin microdosing did not beat placebo on thinking or mood in two blinded trials

Psilocybin · Neuropharmacology, 2025 · Evidence: Moderate

RCT

First human trial of GM-2505, a new short-acting psychedelic drug, in 48 healthy volunteers

Other · Journal of psychopharmacology (Oxford, England), 2025 · Evidence: Moderate

Systematic review

Review of blood and brain markers linked to response to psilocybin and ayahuasca therapy

Psilocybin, Ayahuasca · Therapeutic advances in psychopharmacology, 2025 · Evidence: Low

Systematic review

Review of repeated ketamine "maintenance" doses for hard-to-treat depression

Ketamine · Journal of affective disorders, 2025 · Evidence: Low

Systematic review

Review of brain-imaging studies on ketamine, reward circuits and depression

Ketamine, Other · Journal of affective disorders, 2025 · Evidence: Low

Case report

A 1930 psychiatric case of mescaline use, rediscovered from unpublished hospital notes

Mescaline · Neuropharmacology, 2025 · Evidence: Very low

RCT

Esketamine nasal spray beat quetiapine on quality-of-life measures in hard-to-treat depression

Esketamine · European psychiatry : the journal of the Association of European Psychiatrists, 2025 · Evidence: Moderate

RCT

Oral ketamine for depression: small trial missed its main goal, pooled evidence more positive

Ketamine · Journal of affective disorders, 2025 · Evidence: Moderate

Observational

A new 70-item questionnaire to measure the subjective effects of ibogaine

Ibogaine · PloS one, 2025 · Evidence: Low

Systematic review

Do men and women respond differently to ketamine for depression? Review finds no clear answer

Ketamine · Progress in neuro-psychopharmacology & biological psychiatry, 2025 · Evidence: Low

Other

Comparing visual hallucinations from psychedelics and from Lewy body diseases

Psilocybin, Mescaline, Other · Schizophrenia bulletin, 2025 · Evidence: Very low

RCT

MDMA and methamphetamine tested for effects on blood endocannabinoid levels in healthy adults

MDMA, Other · Psychopharmacology, 2025 · Evidence: Moderate

RCT

DMT plus harmine during a meditation retreat: brain connectivity changes two days later

DMT, Ayahuasca, Other · Imaging neuroscience (Cambridge, Mass.), 2025 · Evidence: Moderate

RCT

MDMA compared with MDA and two lysine prodrugs in 23 healthy volunteers

MDMA, Other · Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2025 · Evidence: Moderate

Case report

Case report: severe muscle breakdown and kidney injury after ayahuasca use

Ayahuasca, DMT · Cureus, 2025 · Evidence: Very low

Systematic review

Review of how ecstasy (MDMA) use affects teeth, gums and jaw health

MDMA, Other · Frontiers in oral health, 2025 · Evidence: Very low

Survey

Large survey looks at difficult mental states after ayahuasca and later mental health

Ayahuasca · PLOS mental health, 2025 · Evidence: Low

Case report

Case report: man hospitalized after ayahuasca use, with other drugs found in his blood

Ayahuasca, DMT · Revista Colombiana de psiquiatria, 2025 · Evidence: Very low